Short duration treatment in genotype 1 chronic hepatitis C patients with rapid virologic response to pegylated interferon plus ribavirin

Biomedicine and Pharmacotherapy

Volumn 65, Issue 4, 2011, Pages 303-306

  Bonardi, Renato ^a   Tabone, Marco ^b   Manca, Aldo ^c   Pellicano, Rinaldo ^a   Ciancio, Alessia ^a   Rizzetto, Mario ^a  

^a MOLINETTE HOSPITAL   (Italy)

^b MAURIZIANO HOSPITAL   (Italy)

^c S CROCE E CARLE HOSPITAL   (Italy)

Author keywords

Chronic hepatitis c; HCV; Interferon

Indexed keywords

PEGINTERFERON ALPHA2A PLUS RIBAVIRIN; VIRUS RNA;

ADULT; AGE DISTRIBUTION; ANTIVIRAL THERAPY; ARTICLE; DRUG EFFICACY; DRUG RESPONSE; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; FEMALE; FOLLOW UP; HEPATITIS C; HUMAN; MAJOR CLINICAL STUDY; MALE; OPEN STUDY; PRIORITY JOURNAL; RAPID VIROLOGICAL RESPONSE; RELAPSE; SHORT COURSE THERAPY; SUSTAINED VIROLOGICAL RESPONSE; VIRAL CLEARANCE;

ADULT; ANTIVIRAL AGENTS; COST-BENEFIT ANALYSIS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; FEMALE; GENOTYPE; HEPACIVIRUS; HEPATITIS C ANTIBODIES; HEPATITIS C, CHRONIC; HUMANS; INTERFERON-ALPHA; LIVER FUNCTION TESTS; MALE; MIDDLE AGED; POLYETHYLENE GLYCOLS; PREDICTIVE VALUE OF TESTS; RECOMBINANT PROTEINS; RECURRENCE; RIBAVIRIN; TIME FACTORS; TREATMENT OUTCOME; VIRAL LOAD;

EID: 79960398654     PISSN: 07533322     EISSN: 19506007     Source Type: Journal    
DOI: 10.1016/j.biopha.2011.03.004     Document Type: Article

References (20)

1. Dienstag J.L., McHutchison J.G. American Gastroenterological Association technical review on the management of hepatitis C. Gastroenterology 2006, 130:231-264.
2. McHutchison J.G., Gordon S.C., Schiff E.R., Shiffman M.L., Lee W.M., Rustgi V.K., et al. Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. N Engl J Med 1998, 339:1485-1492.
3. Fried M.W., Shiffman M.L., Reddy K.R., Smith C., Marinos G., Goncales F.L., et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002, 347:975-982.
4. Manns M.P., McHutchison J.G., Gordon S.C., Rustgi V.K., Shiffman M., Reindollar R., et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 2001, 358:958-965.
5. Xie Y., Xu D.Z., Lu Z.M., Luo K.X., Jia J.D., Wang Y.M., et al. Impact of virus genotype on interferon treatment of patients with chronic hepatitis C: a multicenter controlled study. Hepatobiliary Pancreat Dis Int 2004, 3:369-374.
6. Dienstag J.L., McHutchison J.G. American Gastroenterological Association medical position statement on the management of hepatitis C. Gastroenterology 2006, 130:225-230.
7. McOmish F., Yap P.L., Dow B.C., Follett E.A., Seed C., Keller A.J., et al. Geographical distribution of hepatitis C virus genotypes in blood donors: an international collaborative survey. J Clin Microbiol 1994, 32:884-892.
8. Neumann A.U., Lam N.P., Dahari H., Gretch D.R., Wiley T.E., Layden T.J., et al. Hepatitis C viral dynamics in vivo and the antiviral efficacy of interferon-alfa therapy. Science 1998, 282:103-107.
9. Zeuzem S., Herrmann E., Lee J.-H., Fricke J., Neumann A.U., Modi M., et al. Viral kinetics in patients with chronic hepatitis C treated with standard or peginterferon alfa-2a. Gastroenterology 2001, 120:1438-1447.
10. Ferenci P., Laferl H., Scherzer T.M., Gschwantler M., Maieron A., Brunner H., et al. Peginterferon alfa-2a and ribavirin for 24 weeks in hepatitis C type 1 and four patients with rapid virological response. Gastroenterology 2008, 135:451-458.
11. Jensen D.M., Morgan T.R., Marcellin P., Pockros P.J., Reddy K.R., Hadziyannis S.J., et al. Early identification of HCV genotype 1 patients responding to 24 weeks peginterferon alfa-2a (40 kd)/ribavirin therapy. Hepatology 2006, 43:954-960.
12. Mangia A., Minerva N., Bacca D., Cozzolongo R., Ricci G.L., Carretta V., et al. Individualized treatment duration for hepatitis C genotype 1 patients: a randomized controlled trial. Hepatology 2008, 47:43-50.
13. Zeuzem S., Buti M., Ferenci P., Sperl J., Horsmans Y., Cianciara J., et al. Efficacy of 24 weeks treatment with peginterferon alfa-2b plus ribavirin in patients with chronic hepatitis C infected with genotype 1 and low pretreatment viremia. J Hepatol 2006, 44:97-103.
14. Bihl F., Negro F. Treatment of chronic hepatitis C. Minerva Med 2009, 100:459-465.
15. Yu J.W., Wang G.Q., Sun L.J., Li X.G., Li S.C. Predictive value of rapid virological response and early virological response on sustained virological response in HCV patients treated with pegylated interferon alfa-2a and ribavirin. J Gastroenterol Hepatol 2007, 22:832-836.
16. Rodriguez-Torres M., Sulkowski M., Chung R.T., Hamzeh F., Jensen D.M. Association of pretreatment and on-treatment factors with rapid virological response in HCV genotype 1-infected patients with peginterferon alfa-2a/ribavirin. Hepatology 2007, 46(4):817A.
17. Sanchez-Tapias J.M., Diago M., Escartin P., Enríquez J., Romero-Gómez M., Bárcena R., et al. Peginterferon alfa-2a plus ribavirin for 48 versus 72 weeks in patients with detectable hepatitis C virus RNA at week 4 of treatment. Gastroenterology 2006, 131:451-460.
18. Yu M.L., Dai C.Y., Huang J.F., Chuang W.L. Rapid virological response and treatment duration for chronic hepatitis C genotype 1 patients: a randomized trial. Hepatology 2008, 47:1884-1893.
19. Yu M.L., Dai C.Y., Huang J.F., Chuang W.L. Rapid virological response to peginterferon and ribavirin for hepatitis C genotype 1: the role of weight-based ribavirin exposure. Hepatology 2008, 48:1019-1020.
20. Rumi M., Aghemo A., Prati G.M., D'Ambrosio R., Donato M.F., Soffredini R., et al. Randomized study of peginterferon alfa-2a pus ribavirin vs peginterferon-alfa-2b plus ribavirin in chronic hepatitis C. Gastroenterology 2010, 138:108-115.